News
Enter your email address to get Core One Labs News Alerts.
News
Enter your email address to get Core One Labs News Alerts.
Company News
Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market
December 08, 2023
Vancouver, British Columbia, Canada – December 8, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6,...
Read more
Company News
Core One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment Methods
December 01, 2023
Vancouver, British Columbia, Canada – December 1, 2023 – Core One Labs Inc. (“Core One” or the “Company”) (CSE: COOL), (OTCQB: CLABF),...
Read more
Company News
Core One Labs Closes Non-Brokered Private Placement
September 18, 2023
Vancouver, British Columbia, Canada – September 18, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt:...
Read more
Company News
Core One Labs Announces Non-Brokered Private Placement
September 11, 2023
Vancouver, British Columbia, Canada – September 11, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt:...
Read more
Company News
Core One Labs Commends Study Exploring Psychedelics’ Efficacy in Providing Relief for Chronic Pain Conditions
August 23, 2023
Vancouver, British Columbia, Canada – August 23, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6,...
Read more
Company News
Core One’s Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson’s Disease
August 04, 2023
Vancouver, British Columbia, Canada – August 4, 2023 – Core One Labs Inc. (CSE: COOL) (OTCQB: CLABF) (Frankfurt: LD6, WKN: A3CSSU), (the “Company”...
Read more